JN.1变异株新冠疫苗单剂接种在已接种成人中的安全性与免疫原性:3期开放标签试验主要分析
本研究为3期开放标签单臂试验,评估单剂NVX-CoV2705(JN.1亚变异株重组蛋白疫苗)在既往接种过新冠疫苗的≥18岁成人中的安全性与免疫原性。结果显示,接种后第28天针对JN.1的中和抗体GMT从基线138.6升至671.4,对多种流行变异株GMT增长≥3.8倍,安全性可接受。
要点
- 单剂NVX-CoV2705在既往接种成人中诱导针对JN.1的快速稳健免疫应答。
- 第28天JN.1中和抗体GMT从基线138.6升至671.4。
- 对JN.1及多种流行变异株GMT增长≥3.8倍,安全性可接受。
核心结论
- 单剂NVX-CoV2705可诱导针对Omicron JN.1及其他流行变异株的快速稳健免疫应答,安全性可接受。
研究设计与样本
- 研究2019nCoV-315为3期开放标签单臂试验,在美国纳入≥18岁既往接种新冠疫苗的成人,单剂接种NVX-CoV2705。
- 共筛查66人,入组60人,58人纳入符合方案分析集。
主要发现
- 针对JN.1的中和抗体GMT从基线138.6(95%CI:88.0,218.2)升至第28天671.4(95%CI:437.0,1031.6)。
- 对JN.1、LP.8.1、KP.2、KP.3、KP.3.1.1、MC.1、XEC、MC.10.1、LF.7、LF.7.2.1、LF.7.7.2、NB.1.8.1和XFC等变异株,第28天GMT较基线增长≥3.8倍。
- 单剂接种后安全性可接受。
临床怎么用
- 对于既往接种过新冠疫苗的成人,单剂JN.1变异株疫苗可快速提升针对JN.1及流行变异株的中和抗体水平。
局限性
- 本研究为开放标签单臂设计,未设对照疫苗组。
- 样本量较小,符合方案分析集仅58人。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the immunogenicity and safety of a dose of NVX-CoV2705, a JN.1 subvariant SARS CoV-2 rS vaccine, in adults previously vaccinated with authorized/approved COVID-19 vaccines. METHODS: Study 2019nCoV-315 is a Phase 3, open-label, single-arm study to evaluate the safety and immunogenicity of a single dose of NVX-CoV2705 in previously COVID-19-vaccinated adult participants ≥18 years of age in the United States. Participants received one dose of NVX-CoV2705. The primary immunogenicity endpoint was the geometric mean titer (GMT) of serum neutralizing antibodies against the SARS-CoV-2 Omicron JN.1 variant at Day 28 following study vaccination and seroresponse rate (SRR) in ID50 titers for the JN.1 subvariant assessed at Day 28 following study vaccination. Primary safety endpoints include local and systemic solicited adverse events (AEs) up to Day 6 post-vaccination, unsolicited AEs up to Day 28, and treatment-related MAAEs, AESIs, and SAEs through Day 180. Exploratory endpoints also provided additional data for circulating variants. RESULTS: Between October 14, 2024, and October 15, 2024, 66 participants were screened and 60 enrolled. A total of 58 participants were included in the Per-Protocol Analysis Set. GMTs increased from 138.6 (95 % CI: 88.0, 218.2) to 671.4 (95 % CI: 437.0, 1031.6) from baseline to Day 28, respectively. In addition, GMTs increased ≥3.8-fold (GMFR) from baseline (Day 0) to Day 28 for currently circulating or emerging Omicron subvariants JN.1, LP.8.1, KP.2, KP.3, KP.3.1.1, MC.1, XEC, MC.10.1, LF.7, LF.7.2.1, LF.7.7.2, NB.1.8.1, and XFC, with an acceptable safety profile after single dose vaccination. DISCUSSION: A single dose of NVX-CoV2705 induced a rapid and robust anti-SARS-CoV-2 immune response against the Omicron JN.1 and other circulating variants and had an acceptable safety profile. https://clinicaltrials.gov/study/NCT06409663.
引用
- Alves K, Kouassi A, Nelson J, et al. Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial. Vaccine. 2025. PMID: 41455184. doi:10.1016/j.vaccine.2025.128164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。